What this study adds
Pirfenidone and nintedanib dose-dependently attenuated severe silicosis,
mainly via regulating immune response and metabolic abnormalities. The
low-dose combined-therapy outperformed monotherapy on fibrosis
remission, potentially via synergic mechanisms indicated by multi-omics.